Elvitegravir - Open Access .click

Results 161 to 170 of about 5,420 (200)

Some of the next articles are maybe not open access.

Development and validation of an UPLC-MS/MS bioanalytical method for simultaneous quantification of the antiretroviral drugs dolutegravir, elvitegravir, raltegravir, nevirapine and etravirine in human plasma.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2019
Dolutegravir, elvitegravir, raltegravir, nevirapine and etravirine are antiretroviral drugs used as part of combined antiretroviral treatment for HIV-infection.
P. Bollen +4 more
semanticscholar +1 more source

Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised

The Lancet HIV, 2019
BACKGROUND Tenofovir alafenamide is associated with less renal and bone toxicity than tenofovir disoproxil fumarate and might improve the long-term safety of antiretroviral therapy.
F. Maggiolo +11 more
semanticscholar +1 more source

Elvitegravir

Reactions Weekly, 2021
openaire +1 more source

UPLC-PDA Approach for Simultaneous Quantification of Elvitegravir, Tenofovir, Emtricitabine and Cobicistat in Tablets: An MS-ESI Study for Degradation Products.

Journal of Chromatographic Science, 2023
R. L. Nimmagadda, Sowjanya Gummadi
semanticscholar +1 more source

Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide